Kenya has joined the global efforts in search of an effective vaccine for COVID-19 with the start of a trial evaluating the ChAdOx1 nCoV-2019 Oxford coronavirus vaccine.
The trial will be hosted at KEMRI at its Kilifi based KEMRI-Wellcome Trust Research Programme, a longstanding collaboration between KEMRI, the University of Oxford and the Wellcome Trust in the UK.
Following the necessary approvals from regulators, as well as the national ministry of health, and Kilifi county, the first volunteers for the trial have recently received their vaccinations.
The full story is available on the University of Oxford website